EKLF (KLF1): A Potential Tumor Suppressor?
EKLF (KLF1): A Potential Tumor Suppressor?
批准号:
7901246
负责人:
JAMES J BIEKER
金额:
$22.12万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2012-06-30
关键词:
Acute Myelocytic LeukemiaAddressAntibodiesAttenuatedBiological MarkersBone MarrowBone Marrow CellsCell CycleCell LineCell ProliferationCellsCharacteristicsErythroidEvaluationFamily memberFutureGeneticGenetic TranscriptionGrantHematopoiesisHematopoieticHematopoietic NeoplasmsHigh Pressure Liquid ChromatographyHumanLeadLeukemic CellMalignant - descriptorMalignant NeoplasmsMegakaryocytopoiesesModificationMolecularMutateNaturePatientsPlayPropertyProteinsReagentRepressionRoleSamplingSeriesTestingTimeTimeLineTissuesTumor Suppressor ProteinsVariantZinc Fingersbasecancer cellclinically relevantdesignerythroid Kruppel-like factorinhibitor/antagonistleukemialeukemogenesismutantnovelpreventpublic health relevanceresearch studytranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Functional inactivation of tumor suppressors plays an important role in malignancy. Many tumor suppressors normally interface with the cell cycle machinery and form part of its exquisite control mechanism. Loss of these controls can lead to unrestricted proliferation and impaired differentiation, both of which are characteristic of acute myeloid leukemia. EKLF (Erythroid Kr¿ppel Like Factor; KLF1) is a zinc finger hematopoietic transcription factor that is absolutely critical for the erythroid lineage. Our recent studies have also revealed an unexpected role of EKLF as an inhibitor of megakaryopoiesis, suggesting a novel function of this transcription factor in lineage commitment during hematopoiesis. EKLF inhibits cellular proliferation and induces endogenous expression of the cell cycle inhibitor p21. As a result, we hypothesize that human EKLF may play a role in hematopoietic malignancy consistent with that of a tumor suppressor, and this exploratory proposal will evaluate this idea by two aims. In the first, we will use an antibody that recognizes human EKLF protein to analyze human normal and leukemic tissue and cell samples for the presence/absence of EKLF protein, and determine whether its expression correlates with a specific malignant subtype. In the second, the sequence of the complete human EKLF transcription unit will be compared between normal bone marrow and a number of human leukemic cell lines and malignant primary cells to see if EKLF is mutated in any of these lines. Functional tests of any variant EKLF proteins that are discovered will follow both of these aims and will also provide a basis for future experiments that extend beyond the timeline of this exploratory grant. Successful attainment of the aims in this proposal will determine whether mutated EKLF/KLF1 plays a role in leukemia, thus providing a novel biomarker, and will direct future applicability towards the most clinically relevant samples.
PUBLIC HEALTH RELEVANCE: Tumor suppressors play an important role in preventing malignancy. EKLF, a critical zinc finger hematopoietic transcription factor, has antiproliferative properties consistent with that of a tumor suppressor. As a result, our test hypothesis is that EKLF is playing an unappreciated role as a tumor suppressor, and that its dysregulation can contribute or lead to human leukemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Coordinate regulation of erythroid and macrophage lineages in development by EKLF/KLF1
-
批准号:10553699
-
项目类别:
-
资助金额:$48.68万
-
财政年份:2020
-
负责人:JAMES J BIEKER
-
依托单位:
Coordinate regulation of erythroid and macrophage lineages in development by EKLF/KLF1
-
批准号:10348762
-
项目类别:
-
资助金额:$48.68万
-
财政年份:2020
-
负责人:JAMES J BIEKER
-
依托单位:
Generation of cultured RBCs with rare phenotypes for transfusion from sources usually discarded during regular blood donations
-
批准号:10188596
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2018
-
负责人:JAMES J BIEKER
-
依托单位:
Generation of cultured RBCs with rare phenotypes for transfusion from sources usually discarded during regular blood donations
-
批准号:9789365
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2018
-
负责人:JAMES J BIEKER
-
依托单位:
Intrinsic and extrinsic control of erythropoietic maturation
-
批准号:9042359
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2014
-
负责人:JAMES J BIEKER
-
依托单位:
Intrinsic and extrinsic control of erythropoietic maturation
-
批准号:9258426
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2014
-
负责人:JAMES J BIEKER
-
依托单位:
Intrinsic and extrinsic control of erythropoietic maturation
-
批准号:8714505
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2014
-
负责人:JAMES J BIEKER
-
依托单位:
EKLF (KLF1): A Potential Tumor Suppressor?
-
批准号:8102179
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2010
-
负责人:JAMES J BIEKER
-
依托单位:
Redirecting hemoglobin expression during Human ES Cell differentiation
-
批准号:7814682
-
项目类别:
-
资助金额:$65.76万
-
财政年份:2010
-
负责人:JAMES J BIEKER
-
依托单位:
2009 Red Cells Gordon Research Conference
-
批准号:7670698
-
项目类别:
-
资助金额:$1.9万
-
财政年份:2009
-
负责人:JAMES J BIEKER
-
依托单位:
Bipotential lineage determination by EKLF
-
批准号:8306853
-
项目类别:
-
资助金额:$34.83万
-
财政年份:2008
-
负责人:JAMES J BIEKER
-
依托单位:
Bipotential lineage determination by EKLF
-
批准号:7673993
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2008
-
负责人:JAMES J BIEKER
-
依托单位:
Bipotential lineage determination by EKLF
-
批准号:8125095
-
项目类别:
-
资助金额:$34.83万
-
财政年份:2008
-
负责人:JAMES J BIEKER
-
依托单位:
GROWTH, DIFFERENTIATION AND GENETIC ALTERATION OF HUMAN ES CELLS
-
批准号:7092815
-
项目类别:
-
资助金额:$5.56万
-
财政年份:2005
-
负责人:JAMES J BIEKER
-
依托单位:
PNA-based strategies to reverse gamma-globin gene silencing*
-
批准号:6722862
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2003
-
负责人:JAMES J BIEKER
-
依托单位:
PNA-based strategies to reverse gamma-globin gene silenc
-
批准号:6614271
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2003
-
负责人:JAMES J BIEKER
-
依托单位:
PNA-based strategies to reverse gamma-globin gene silencing*
-
批准号:6877184
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2003
-
负责人:JAMES J BIEKER
-
依托单位:
PNA-based strategies to reverse gamma-globin gene silencing*
-
批准号:7034540
-
项目类别:
-
资助金额:$33.1万
-
财政年份:2003
-
负责人:JAMES J BIEKER
-
依托单位:
TRANSCRIPTIONAL REGULATION OF HEMOGLOBIN SWITCHING
-
批准号:6667513
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2002
-
负责人:JAMES J BIEKER
-
依托单位:
TRANSCRIPTIONAL REGULATION OF HEMOGLOBIN SWITCHING
-
批准号:6584641
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2002
-
负责人:JAMES J BIEKER
-
依托单位:
海外基金